Study summary
In teenagers, nivolumab with chemotherapy worked better with very little radiation
93% vs 82%free of progression at 3 years, nivolumab vs brentuximab
What was tested
The 240 teenagers aged 12 to 17 in the S1826 trial, followed for 3 years.
What they found
- At 3 years, 93% on nivolumab-AVD and 82% on brentuximab-AVD had no progression.
- Only three teenagers in total needed radiation.
- Nerve damage was more common with brentuximab (14% vs 7%); thyroid problems occurred in 7% with nivolumab.
What it means
Avoiding radiation matters for young people, who would otherwise face decades of late effects.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.